{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:30:40Z","timestamp":1792798240942,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.xops.2022.100213","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T12:44:29Z","timestamp":1660913069000},"page":"100213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["A Clinical and Preclinical Assessment of Clinical Trials for Dry Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"2","author":[{"given":"Muhammad","family":"Abidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Karrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Csaky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2022.100213_bib1","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.xops.2022.100213_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40662-016-0063-5","article-title":"Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors","volume":"3","author":"Pennington","year":"2016","journal-title":"Eye Vis (Lond)"},{"key":"10.1016\/j.xops.2022.100213_bib3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.122.4.564","article-title":"Prevalence of age-related macular degeneration in the United States","volume":"122","author":"Friedman","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2022.100213_bib4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1001\/jamaophthalmol.2013.6636","article-title":"Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36","volume":"132","author":"Chew","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2022.100213_bib5","first-page":"CD006537","article-title":"Laser treatment of drusen to prevent progression to advanced age-related macular degeneration","volume":"10","author":"Virgili","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.xops.2022.100213_bib6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/bjo.2008.150334","article-title":"Functional aspects of drusen regression in age-related macular degeneration","volume":"93","author":"Sallo","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2022.100213_bib7","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/IAE.0000000000001392","article-title":"The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target","volume":"37","author":"Boyer","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.xops.2022.100213_bib8","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1167\/iovs.17-22339","article-title":"Report from the NEI\/FDA endpoints workshop on age-related macular degeneration and inherited retinal diseases","volume":"58","author":"Csaky","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2022.100213_bib9","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.oret.2020.12.002","article-title":"Geographic atrophy growth is strongly related to lesion perimeter: unifying effects of lesion area, number, and circularity on growth","volume":"5","author":"Shen","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2022.100213_bib10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ophtha.2010.08.018","article-title":"Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography","volume":"118","author":"Yehoshua","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2022.100213_bib11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ng.3448","article-title":"A\u00a0large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants","volume":"48","author":"Fritsche","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.xops.2022.100213_bib12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1126\/science.1109557","article-title":"Complement factor H polymorphism in age-related macular degeneration","volume":"308","author":"Klein","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.xops.2022.100213_bib13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1126\/science.1110189","article-title":"Complement factor H polymorphism and age-related macular degeneration","volume":"308","author":"Edwards","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.xops.2022.100213_bib14","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.1073\/pnas.0501536102","article-title":"A\u00a0common haplotype in the complement regulatory gene factor H (HF1\/CFH) predisposes individuals to age-related macular degeneration","volume":"102","author":"Hageman","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.xops.2022.100213_bib15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1126\/science.1110359","article-title":"Complement factor H variant increases the risk of age-related macular degeneration","volume":"308","author":"Haines","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.xops.2022.100213_bib16","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/hmg\/ddi353","article-title":"Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk","volume":"14","author":"Rivera","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.xops.2022.100213_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/444437","article-title":"Susceptibility genes for age-related maculopathy on chromosome 10q26","volume":"77","author":"Jakobsdottir","year":"2005","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.xops.2022.100213_bib18","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jama.1996.03540140035023","article-title":"A\u00a0prospective study of cigarette smoking and risk of age-related macular degeneration in men","volume":"276","author":"Christen","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.xops.2022.100213_bib19","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archopht.116.8.1031","article-title":"Smoking and age-related macular degeneration. The POLA Study. Pathologies Oculaires Liees a l'Age","volume":"116","author":"Delcourt","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2022.100213_bib20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/oxfordjournals.aje.a116659","article-title":"The beaver dam eye study: the relation of age-related maculopathy to smoking","volume":"137","author":"Klein","year":"1993","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.xops.2022.100213_bib21","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jama.1996.03540140029022","article-title":"A\u00a0prospective study of cigarette smoking and age-related macular degeneration in women","volume":"276","author":"Seddon","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.xops.2022.100213_bib22","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1001\/archopht.1996.01100140393005","article-title":"Age-related macular degeneration and smoking. The Rotterdam Study","volume":"114","author":"Vingerling","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2022.100213_bib23","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3390\/ijerph8020613","article-title":"Hazardous compounds in tobacco smoke","volume":"8","author":"Talhout","year":"2011","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.xops.2022.100213_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cair.2006.04.002","article-title":"The effect of cigarette smoke-derived oxidants on the inflammatory response of the lung","volume":"6","author":"Foronjy","year":"2006","journal-title":"Clin Appl Immunol Rev"},{"key":"10.1016\/j.xops.2022.100213_bib25","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.tem.2009.04.001","article-title":"Mitochondrial generation of free radicals and hypoxic signaling","volume":"20","author":"Poyton","year":"2009","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.xops.2022.100213_bib26","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1167\/iovs.10-5429","article-title":"Mitochondrial DNA damage as a potential mechanism for age-related macular degeneration","volume":"51","author":"Karunadharma","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2022.100213_bib27","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1167\/iovs.05-0976","article-title":"Proteomics of the retinal pigment epithelium reveals altered protein expression at progressive stages of age-related macular degeneration","volume":"47","author":"Nordgaard","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2022.100213_bib28","doi-asserted-by":"crossref","first-page":"7304","DOI":"10.1523\/JNEUROSCI.0190-15.2015","article-title":"Investigating mitochondria as a target for treating age-related macular degeneration","volume":"35","author":"Terluk","year":"2015","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.xops.2022.100213_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf1443","article-title":"Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration","volume":"9","author":"Yaspan","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.xops.2022.100213_bib30","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2022.100213_bib31","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.molimm.2005.12.002","article-title":"Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3","volume":"43","author":"Soulika","year":"2006","journal-title":"Mol Immunol"},{"key":"10.1016\/j.xops.2022.100213_bib32","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.imbio.2012.06.003","article-title":"New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties","volume":"218","author":"Qu","year":"2013","journal-title":"Immunobiology"},{"key":"10.1016\/j.xops.2022.100213_bib33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2022.100213_bib35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J\u00a0Prev Alzheimers Dis"},{"key":"10.1016\/j.xops.2022.100213_bib36","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 trial","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2022.100213_bib37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ophtha.2013.09.044","article-title":"Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study","volume":"121","author":"Yehoshua","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2022.100213_bib38","author":"Heier"},{"key":"10.1016\/j.xops.2022.100213_bib40","first-page":"1236","article-title":"Photoreceptor loss in age-related macular degeneration","volume":"37","author":"Curcio","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2022.100213_bib41","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ophtha.2022.02.001","article-title":"Photoreceptor layer thinning is an early biomarker for age-related macular degeneration: epidemiologic and genetic evidence from UK Biobank OCT data","volume":"129","author":"Zekavat","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2022.100213_bib42","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ajo.2018.02.012","article-title":"Visual function metrics in early and intermediate dry age-related macular degeneration for use as clinical trial endpoints","volume":"189","author":"Cocce","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2022.100213_bib43","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.ophtha.2006.12.023","article-title":"Cone- and rod-mediated dark adaptation impairment in age-related maculopathy","volume":"114","author":"Owsley","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2022.100213_bib44","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ophtha.2015.09.041","article-title":"Delayed rod-mediated dark adaptation is a functional biomarker for incident early age-related macular degeneration","volume":"123","author":"Owsley","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2022.100213_bib45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ajo.2021.01.017","article-title":"Normal- and low-luminance automated quantitative contrast sensitivity assessment in eyes with age-related macular degeneration","volume":"226","author":"Ou","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2022.100213_bib46","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ophtha.2018.09.039","article-title":"Longitudinal study of dark adaptation as a functional outcome measure for age-related macular degeneration","volume":"126","author":"Chen","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2022.100213_bib47","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.ophtha.2008.03.009","article-title":"Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration","volume":"115","author":"Sunness","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2022.100213_bib48","doi-asserted-by":"crossref","first-page":"7310","DOI":"10.1167\/iovs.11-8649","article-title":"Impaired mesopic visual acuity in eyes with early age-related macular degeneration","volume":"53","author":"Puell","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2022.100213_bib49","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/bjophthalmol-2020-318494","article-title":"Contrast sensitivity function in patients with macular disease and good visual acuity","volume":"106","author":"Wai","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2022.100213_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100095","article-title":"Phase 1 clinical trial of elamipretide in intermediate age-related macular degeneration and high-risk drusen: ReCLAIM high-risk drusen study","volume":"2","author":"Allingham","year":"2022","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.xops.2022.100213_bib51","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1159\/000513591","article-title":"Use of composite end points in early and intermediate age-related macular degeneration clinical trials: state-of-the-art and future directions","volume":"244","author":"Terheyden","year":"2021","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.xops.2022.100213_bib52","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Fleckenstein","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2022.100213_bib53","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0161-6420(97)30079-7","article-title":"Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity","volume":"104","author":"Sunness","year":"1997","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2022.100213_bib54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ajo.2021.06.017","article-title":"Phase 1 study of the anti-HtrA1 antibody-binding fragment FHTR2163 in geographic atrophy secondary to age-related macular degeneration","volume":"232","author":"Khanani","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2022.100213_bib55","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2103617118","article-title":"Chromosome 10q26-driven age-related macular degeneration is associated with reduced levels of HTRA1 in human retinal pigment epithelium","volume":"118","author":"Williams","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.xops.2022.100213_bib56","doi-asserted-by":"crossref","first-page":"AMD143","DOI":"10.1167\/iovs.18-24245","article-title":"An acute injury model for the phenotypic characteristics of geographic atrophy","volume":"59","author":"Bhutto","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2022.100213_bib57","doi-asserted-by":"crossref","first-page":"7475","DOI":"10.1038\/s41598-019-43906-z","article-title":"A\u00a0lasered mouse model of retinal degeneration displays progressive outer retinal pathology providing insights into early geographic atrophy","volume":"9","author":"Ibbett","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2022.100213_bib58","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/ars.2017.7084","article-title":"Oxidative stress induces an interactive decline in Wnt and Nrf2 signaling in degenerating retinal pigment epithelium","volume":"29","author":"Ebrahimi","year":"2018","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.xops.2022.100213_bib59","doi-asserted-by":"crossref","first-page":"13094","DOI":"10.1073\/pnas.2000339117","article-title":"Altered photoreceptor metabolism in mouse causes late stage age-related macular degeneration-like pathologies","volume":"117","author":"Cheng","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.xops.2022.100213_bib60","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1038\/s41467-019-11262-1","article-title":"A\u00a0systems biology approach towards understanding and treating non-neovascular age-related macular degeneration","volume":"10","author":"Handa","year":"2019","journal-title":"Nat Commun"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914522001026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914522001026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:20:54Z","timestamp":1763014854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914522001026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2666914522001026"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2022.100213","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Clinical and Preclinical Assessment of Clinical Trials for Dry Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2022.100213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100213"}}